[go: up one dir, main page]

MXPA05002418A - Derivados de 1,4-pirazina sustituidos. - Google Patents

Derivados de 1,4-pirazina sustituidos.

Info

Publication number
MXPA05002418A
MXPA05002418A MXPA05002418A MXPA05002418A MXPA05002418A MX PA05002418 A MXPA05002418 A MX PA05002418A MX PA05002418 A MXPA05002418 A MX PA05002418A MX PA05002418 A MXPA05002418 A MX PA05002418A MX PA05002418 A MXPA05002418 A MX PA05002418A
Authority
MX
Mexico
Prior art keywords
substituted
pyrazine derivatives
pyrazine
derivatives
depression
Prior art date
Application number
MXPA05002418A
Other languages
English (en)
Inventor
Robert L Hoffman
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MXPA05002418A publication Critical patent/MXPA05002418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen derivados sustituidos de aril 1,4-pirazina y su uso para tratar trastornos de ansiedad, depresion y trastornos relacionados con el estres.
MXPA05002418A 2002-09-12 2003-08-27 Derivados de 1,4-pirazina sustituidos. MXPA05002418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12
PCT/US2003/024805 WO2004024719A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Publications (1)

Publication Number Publication Date
MXPA05002418A true MXPA05002418A (es) 2005-05-27

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002418A MXPA05002418A (es) 2002-09-12 2003-08-27 Derivados de 1,4-pirazina sustituidos.

Country Status (10)

Country Link
US (1) US20040116444A1 (es)
EP (1) EP1539736A1 (es)
JP (1) JP2006506350A (es)
AR (1) AR041125A1 (es)
AU (1) AU2003269949A1 (es)
BR (1) BR0314139A (es)
CA (1) CA2494975A1 (es)
MX (1) MXPA05002418A (es)
TW (1) TW200503717A (es)
WO (1) WO2004024719A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524519A1 (en) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Compounds as crf1 receptor antagonists
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
SG11201906209SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Bicyclic compounds as allosteric shp2 inhibitors
BR112020004246A2 (pt) 2017-09-07 2020-09-01 Revolution Medicines, Inc. composições inibidoras de shp2 e métodos para o tratamento de câncer
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
KR20200099530A (ko) 2017-12-15 2020-08-24 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 다환식 화합물
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
PE20252397A1 (es) 2018-05-01 2025-10-10 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor
EP4531859A1 (en) 2022-05-25 2025-04-09 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
DE60114153T2 (de) * 2000-02-16 2006-07-06 Neurogen Corp., Branford Substituierte arylpyrazine

Also Published As

Publication number Publication date
WO2004024719A1 (en) 2004-03-25
BR0314139A (pt) 2005-07-12
JP2006506350A (ja) 2006-02-23
EP1539736A1 (en) 2005-06-15
AU2003269949A1 (en) 2004-04-30
TW200503717A (en) 2005-02-01
CA2494975A1 (en) 2004-03-25
US20040116444A1 (en) 2004-06-17
AR041125A1 (es) 2005-05-04

Similar Documents

Publication Publication Date Title
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
EP1583821A4 (en) METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
CA105223S (en) Sponge
TW200503705A (en) 3-amino chroman and 2-amino tetralin derivatives
CA100209S (en) Handle
DE60237431D1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
NO20034364L (no) Sapogenin-derivater, deres syntese og anvendelse samt metoder basert pa deres anvendelse
TW200503717A (en) Substituted 1,4-pyrazine derivatives
EP1470240A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
WO2003063796A3 (en) Heterocyclic arylsulfonamidobenzylic compounds
DK1220852T3 (da) Substituerede diazepaner
DE60324104D1 (en) Arylsulfonamidobenzylverbindungen
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
AU2003278927A1 (en) 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
TR200200278T2 (tr) Kalsilitik bileşimler
EP1471818A4 (en) METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
NO20060420L (no) 2-aminobenzoylderivater
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
CA102620S (en) Sphygmomanometer
CA101943S (en) Plate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal